Equities researchers at StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) in a research note issued on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.
Cumberland Pharmaceuticals Price Performance
Shares of Cumberland Pharmaceuticals stock opened at $1.64 on Wednesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.28 and a quick ratio of 1.11. Cumberland Pharmaceuticals has a one year low of $1.43 and a one year high of $2.36. The business’s 50 day simple moving average is $1.86 and its two-hundred day simple moving average is $1.88. The stock has a market capitalization of $23.25 million, a P/E ratio of -3.73 and a beta of 0.16.
Cumberland Pharmaceuticals (NASDAQ:CPIX – Get Free Report) last issued its earnings results on Tuesday, March 5th. The specialty pharmaceutical company reported ($0.12) EPS for the quarter. The firm had revenue of $9.35 million during the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.84% and a negative net margin of 15.87%.
Institutional Trading of Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Read More
- Five stocks we like better than Cumberland Pharmaceuticals
- 5 discounted opportunities for dividend growth investors
- Charles Schwab Fortifies its Uptrend on EPS Beat
- Want to Profit on the Downtrend? Downtrends, Explained.
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.